Pakistan Strengthens Hepatitis Delta Response Through International Collaboration
ISLAMABAD - The Ministry of National Health Services, Regulations and Coordination, in partnership with the Drug Regulatory Authority of Pakistan (DRAP), has initiated a comprehensive strategy to tackle the escalating threat of Hepatitis Delta Virus (HDV) across the nation. This approach combines international cooperation with plans for domestic pharmaceutical manufacturing to enhance treatment accessibility.
High-Level Meeting with Chinese Pharmaceutical Firm
Federal Minister for Health, Syed Mustafa Kamal, presided over a crucial meeting that included representatives from the prominent Chinese pharmaceutical company Huahui Health, alongside other key stakeholders. The session was dedicated to evaluating and refining strategies to counter the rapid spread of the Hepatitis Delta virus in Pakistan.
During the discussions, Huahui Health provided an update on its innovative Hepatitis Delta therapy, HH-003, which has recently concluded successful Phase II international clinical trials. This therapy has already secured regulatory approval in China, backed by demonstrated safety and efficacy. Additionally, the U.S. Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation, underscoring its potential to deliver substantial improvements in treatment outcomes.
Understanding the Hepatitis Delta Challenge in Pakistan
Minister Mustafa Kamal highlighted that Hepatitis Delta is becoming a significant public health issue in Pakistan. He explained that HDV is a particularly dangerous virus that targets the liver and can only infect individuals who are already carrying Hepatitis B (HBV). Given the high prevalence of Hepatitis B in the country, HDV presents an additional and severe health burden.
Estimates indicate that over one million people in Pakistan may be affected by Hepatitis Delta. Health experts have cautioned that without prompt diagnosis and effective treatment, the disease can progress to liver cirrhosis and liver cancer. Statistics reveal that approximately 20 percent of Hepatitis B patients in Pakistan might also be co-infected with Hepatitis Delta. However, due to the absence of routine diagnostic testing, many cases remain undetected.
Government Initiatives for Local Production and Access
The Federal Minister announced that the government will actively support partnerships between Huahui Health and leading local pharmaceutical companies to facilitate technology transfer and the local production of advanced biological medicines. This initiative is designed to ensure affordable, sustainable, and long-term access to life-saving treatments for Pakistani patients.
He reaffirmed the government's commitment to providing the public with safe, high-quality, and innovative medicines as a top priority. DRAP, he noted, will maintain a transparent, science-based regulatory approval process that aligns with international standards.
Accelerating Clinical Trials and Future Steps
All stakeholders agreed to expedite the regulatory procedures for Phase III clinical trials in Pakistan. This move aims to enable the new therapy to reach eligible patients as quickly as possible, under strict monitoring and adherence to global best practices.
The meeting concluded with a shared dedication to strengthening Pakistan's response to Hepatitis Delta through coordinated policy actions, early diagnosis, and the implementation of modern treatment solutions.
